Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Electron Transport Chain

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Atibuclimab (IC14) for Treatment of Acute Decompensated Heart Failure: A Phase Ib Pilot Study.

JACC. Basic to translational science·2026

Same author

Mitofilin Preservation Mitigates Cardiac Injury in Donation-After-Circulatory-Death Hearts.

Cells·2026

Same author

Alpha-1 antitrypsin: therapeutic applications beyond serine protease inhibition.

Expert opinion on investigational drugs·2026

Same author

INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA.

medRxiv : the preprint server for health sciences·2026

Same author

Metformin improves cardiac stress tolerance and mitochondrial function during early aging.

Experimental gerontology·2026

Same author

Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity.

JACC. CardioOncology·2026

Search research articles

Related Experiment Video

Updated: Aug 4, 2025

Pre-clinical Model of Cardiac Donation after Circulatory Death

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

Electron Transport Chain Inhibition to Decrease Injury in Transplanted Donation After Circulatory Death Rat Hearts.

Mohammed Quader^1,2,3, Qun Chen^3,4, Oluwatoyin Akande¹

¹Division of Cardio-Thoracic Surgery, Department of Surgery, Virginia Commonwealth University, Richmond, VA.

Journal of Cardiovascular Pharmacology

|March 30, 2023

Summary

This summary is machine-generated.

Amobarbital (AMO) treatment improves heart function in donation after circulatory death (DCD) hearts. This intervention reduces reactive oxygen species generation, making DCD hearts viable for transplantation.

More Related Videos

Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies

Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies

Published on: October 4, 2024

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Aug 4, 2025

Pre-clinical Model of Cardiac Donation after Circulatory Death

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies

Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies

Published on: October 4, 2024

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death

Published on: June 6, 2025

Area of Science:

Cardiology
Transplantation Immunology
Biochemistry

Background:

Donation after circulatory death (DCD) donor hearts experience ischemic damage, limiting their use in transplantation.
Reperfusion injury in DCD hearts is linked to reactive oxygen species (ROS) from mitochondrial complex I.
Amobarbital (AMO) inhibits mitochondrial complex I, reducing ROS generation.

Purpose of the Study:

To investigate the protective effects of amobarbital (AMO) on transplanted donation after circulatory death (DCD) hearts.
To assess if AMO treatment can mitigate ischemic and reperfusion injury in DCD donor hearts.

Main Methods:

A rat model was used with four groups: DCD, DCD + AMO, control beating-heart donor (CBD), and CBD + AMO.
DCD hearts underwent 25 minutes of in-vivo ischemia before procurement.
Amobarbital (2 mM) was added to the University of Wisconsin cardioplegia solution for AMO groups during procurement.
Heterotopic heart transplantation was performed, and cardiac function was assessed after 14 days.

Main Results:

DCD hearts showed significantly lower developed pressure compared to CBD hearts.
Amobarbital treatment significantly improved cardiac function in transplanted DCD hearts.
AMO treatment in DCD hearts resulted in functional recovery comparable to CBD hearts.

Conclusions:

Amobarbital effectively improves cardiac function in transplanted DCD hearts.
AMO's ability to inhibit mitochondrial complex I and reduce ROS offers a promising strategy to enhance DCD heart utilization.
This study suggests AMO as a potential therapeutic agent to improve outcomes in DCD heart transplantation.